Pricing Log in Create free account
Saturday 17 October 2026 Export RVTY’s income statement to Excel — free account

Revvity Inc.

RVTY Healthcare Diagnostics & Research

Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024. In the quarter to June 2026, revenue grew 1.31%, EPS grew 2.17%, free cash flow grew 59.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years.

152.64 2.07 −1.34%
Market cap
$17.3B
P/E
72.7×
Fwd P/E
37.5×
Dividend yield
0.23%
F-score
6/9
Altman Z
2.49
Beneish M
−2.45
Dividend safety
80/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 5.97
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — 5 — 1 — — 1 — 2 1
Insider Ownership 0.47%

Capital & Financial Ratios $m

Market Cap 17,260.00
Revenue 2,911.81
Net Income 237.55
Free Cash Flow 570.15
Net Debt 2,182.31
Current Ratio 1.80 (at or above 1.5: strong)
Debt/Equity 0.44 (at or below 0.5: strong)
P/E ratio 72.69 (above 35: high)
Fwd P/E 37.50 (above 35: high)
P/S ratio 5.85
P/B ratio 2.36
Past 5Y EPS Growth (20.43%) (below 0%: weak)
This Y EPS Growth 5.86%
Next Y EPS Growth 10.00%
Next Y revenue growth (30.17%) (below 0%: weak)
Next 5Y EPS Growth 8.51%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 6.6×, against a ten-year median of 4.8×; over the ten years it ranged from 2.9× in 2016 to 7.5× in 2022.
P/E against its own 10 years 92.48%
10-year low 10-year high
P/S against its own 10 years 95.76%
10-year low 10-year high
P/B against its own 10 years 35.79%
10-year low 10-year high
EV/Sales against its own 10 years 90.49%
10-year low 10-year high
EV/FCF against its own 10 years 62.79%
10-year low 10-year high

Dividends

Payout Ratio 0.17
Annual Dividend Rate 0.35
Annual Dividend Yield 0.23%
total individual payouts
2028 Powerpack
2027 Powerpack
2026 0.20
0.07
0.07
0.07
0.07
2025 0.21
0.07
0.07
0.07
0.07
2024 0.28
0.07
0.07
0.07
0.07
2023 0.28
0.07
0.07
0.07
0.07
2022 0.28
0.07
0.07
0.07
0.07
2021 0.28
0.07
0.07
0.07
0.07
2020 0.28
0.07
0.07
0.07
0.07
2019 0.28
0.07
0.07
0.07
0.07
2018 0.28
0.07
0.07
0.07
0.07
2017 0.28
0.07
0.07
0.07
0.07
2016 0.28
0.07
0.07
0.07
0.07
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1,603 1,163 920 1,023
Receivables 633 632 745 709
Inventory 428 368 379 379
Other 337 186 196 187
3,001 2,350 2,240 2,298
2023 2024 2025 Q'26
Payables 204 167 185 166
ST’ Debt 722 0 589 572
Other — — — —
1,450 653 1,331 1,276

Compound Annual Growth %

10y 5y 3y
Sales 3.10% 1.41% (4.82%)
Cash Flow 7.34% (8.16%) (5.00%)
Earnings 1.28% (19.82%) (24.89%)
Book Value 13.14% 14.18% (0.60%)

Revenue $m

Mar Jun Sep Dec Year
’26 711 730 — — —
’25 665 720 699 772 2,856
’24 650 692 684 729 2,755
’23 675 709 671 696 2,751
’22 963 896 712 741 3,312
’21 1,308 1,228 861 430 3,828
’20 652 812 964 235 2,663
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 115 192 — — —
’25 128 134 139 182 583
’24 148 159 148 174 628
’23 63 (135) (33) 197 91
’22 283 97 160 139 680
’21 474 288 314 336 1,411
’20 60 139 211 482 892
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 104 184 — — —
’25 112 115 120 162 509
’24 130 137 126 150 542
’23 43 (149) (56) 172 10
’22 256 78 153 107 594
’21 459 267 291 307 1,325
’20 40 124 192 478 833
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.36 0.47 — — —
’25 0.35 0.46 0.40 0.87 2.07
’24 0.21 0.45 0.77 0.78 2.20
’23 4.50 0.28 0.08 0.64 5.55
’22 1.40 1.42 0.67 1.09 4.58
’21 3.37 2.19 1.11 1.41 7.99
’20 0.30 1.23 1.57 3.38 6.49
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.6
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 39.50 50.59 70.74 72.16 62.91 119.95 113.46 79.50 97.32 81.36

Analyst estimates 2026–2028

Powerpack
High 57.28 74.12 98.33 103.00 149.95 203.16 201.05 145.35 129.50 128.29
People
People Employees 8,000 11,000 12,500 13,000 14,000 16,700 16,700 11,500 11,000 11,000
Revenue/emp, $m 0.26 0.21 0.22 0.22 0.19 0.23 0.20 0.24 0.25 0.26
Income, $m
Income, $m Revenue 2,116 2,257 2,778 2,884 2,663 3,828 3,312 2,751 2,755 2,856
Gross margin, % 47.95 47.57 48.27 48.41 64.97 63.59 60.08 55.98 55.81 54.77
EBT 244 297 258 237 800 1,204 652 183 316 268
EBT margin, % 11.54 13.15 9.28 8.22 30.04 31.44 19.68 6.65 11.47 9.39
Net income 234 293 238 228 728 943 569 693 270 241
Depreciation 103 114 203 239 207 352 480 439 434 410
Per share, $
Per share, $ Revenue 19.32 20.54 25.13 26.02 23.88 32.95 26.25 22.06 22.44 24.51
Earnings 2.12 2.64 2.13 2.04 6.49 7.99 4.58 5.55 2.20 2.07
Cash flow 3.20 2.63 2.81 3.28 8.00 12.14 5.39 0.73 5.12 5.00
Capex (0.10) (0.35) (0.50) (0.73) (0.53) (0.74) (0.68) (0.65) (0.71) (0.63)
Free cash flow 3.10 2.28 2.31 2.55 7.47 11.40 4.71 0.08 4.41 4.37
Book value 19.67 22.79 23.38 25.39 33.50 61.48 58.52 63.13 62.46 62.21
Shares, m 109 110 111 111 112 116 126 125 123 117
Valuation, ×
Valuation, × P/E 24.88 28.00 36.88 47.60 22.15 24.88 30.82 20.08 50.50 46.51
P/S 2.74 3.60 3.13 3.73 6.01 6.10 5.38 5.01 4.97 3.95
P/B 2.69 3.24 3.36 3.82 4.28 3.27 2.41 1.75 1.79 1.56
EV/Sales 3.07 4.40 3.75 4.38 6.61 7.25 6.57 5.84 5.69 4.75
EV/FCF 19.09 39.62 40.71 44.73 21.25 21.02 36.91 3,276.43 29.23 26.91
Cash, $m
Cash, $m Operating cash flow 351 288 311 363 892 1,411 680 91 628 583
Capex (11) (38) (55) (81) (59) (86) (86) (81) (87) (74)
Free cash flow 340 250 256 283 833 1,325 594 10 542 509
Balance, $m
Balance, $m Working capital 587 249 463 612 587 1,227 1,744 1,551 1,697 909
Total debt 1,046 2,006 1,891 2,074 1,991 4,984 4,394 3,900 3,151 3,220
Net debt 687 1,804 1,728 1,882 1,589 4,381 3,940 2,297 1,987 2,300
Shareholders’ equity 2,154 2,503 2,585 2,814 3,735 7,141 7,383 7,873 7,667 7,250
Returns, %
Returns, % ROA 5.55 5.64 3.94 3.64 10.04 8.22 3.91 5.01 2.08 1.96
ROIC 6.48 4.29 4.69 4.82 10.18 6.83 4.10 1.85 2.24 2.33
ROE 10.99 12.57 9.35 8.43 22.23 17.34 7.84 9.09 3.48 3.23
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Revvity Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DGX Quest Diagnostics Incorporated $26.4B 24.6× 20.8× +10.21% (above 0%: growing) +14.74% (above 0%: growing) +5.28% (above 0%: growing) 33.75% 15.08% Compare
LH Labcorp Holdings Inc. $26.4B 26.2× 19.0× +5.78% (above 0%: growing) +28.42% (above 0%: growing) −42.01% (below 0%: shrinking) 29.80% 12.10% Compare
GH Guardant Health, Inc. $22.3B — (loss-making) — (loss-making) +44.33% (above 0%: growing) n/m −5.46% (below 0%: shrinking) 65.39% (38.55%) Compare
MEDP Medpace Holdings, Inc. $17.6B 35.6× 26.7× +17.24% (above 0%: growing) +36.39% (above 0%: growing) −3.03% (below 0%: shrinking) 71.36% 20.76% Compare
RVTY Revvity Inc. $17.3B 72.7× 37.5× +1.31% (above 0%: growing) +2.17% (above 0%: growing) +59.29% (above 0%: growing) 57.13% 12.24%
CRL Charles River Laboratories International, Inc. $14.6B — (loss-making) 29.6× −2.72% (below 0%: shrinking) n/m −12.22% (below 0%: shrinking) 36.19% 11.94% Compare
ICLR ICON PLC $13.5B 254× 23.8× +1.20% (above 0%: growing) −59.31% (below 0%: shrinking) +109.66% (above 0%: growing) 23.23% 6.68% Compare
QGEN QIAGEN N.V. $9.5B 23.6× 17.5× +0.28% (above 0%: growing) +7.94% (above 0%: growing) +30.45% (above 0%: growing) 63.62% 24.75% Compare
TWST Twist Bioscience Corporation $9.5B — (loss-making) — (loss-making) +23.24% (above 0%: growing) n/m −7.23% (below 0%: shrinking) 52.76% (30.65%) Compare
Median of peers $16.1B 26.2× 22.3× +8.00% +14.74% −4.24% 44.48% 12.02%

All 52 Diagnostics & Research stocks →

RVTY metrics, ten years each

Revvity Inc. (RVTY) key facts

  • Concern: Net income was $241.2 million, or $2.07 per share (basic), a net margin of 8.45%.
  • Strength: Revvity Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 3.67% from fiscal 2024.
  • Revvity Inc. (RVTY) is a Diagnostics & Research company in the Healthcare sector, listed on the New York Stock Exchange.
  • As of October 16, 2026, RVTY traded at $152.64, a market capitalization of $17.3 billion.
  • At that price the stock trades at 72.7× trailing-twelve-month earnings and 5.8× sales; its P/E is higher than 92% of its own readings over the past ten years.
  • Revvity Inc. pays an annual dividend of $0.35 per share, a yield of 0.23%, with a payout ratio of 16.7%.
  • Return on equity was 3.23% and debt-to-equity 0.44.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.49 (grey zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Revvity Inc. (RVTY) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/RVTY · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com